A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

  • Gilbertson, Michael (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: SVHM HREC Ref 235/19
NMA SSA Reference Number: SSA/59535/MonH-2020-232288(v2)
Monash Health Reference: RES-20-0000-577X
Effective start/end date16/09/2015/09/25


  • clinical trial
  • phase 2 study
  • treatment efficacy
  • lymphoma